MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/annrheumdis-2020-217033

Медицинская библиотека · Annals of the rheumatic diseases · 2020

Machine learning predicts stem cell transplant response in severe scleroderma.

Franks Jennifer M, Martyanov Viktor, Wang Yue, Wood Tammara A, Pinckney Ashley, Crofford Leslie J, Keyes-Elstein Lynette, Furst Daniel E, Goldmuntz Ellen, Mayes Maureen D, McSweeney Peter, Nash Richard A, Sullivan Keith M, Whitfield Michael L

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated clinical benefit of haematopoietic stem cell transplant (HSCT) compared with cyclophosphamide (CYC). We mapped PBC (peripheral blood cell) samples from the SCOT clinical trial to scleroderma intrinsic subsets and tested the hypothesis that they predict long-term response to HSCT.

METHODS

We analysed gene expression from PBCs of SCOT participants to identify differential treatment response. PBC gene expression data were generated from 63 SCOT participants at baseline and follow-up timepoints. Participants who completed treatment protocol were stratified by intrinsic gene expression subsets at baseline, evaluated for event-free survival (EFS) and analysed for differentially expressed genes (DEGs).

RESULTS

Participants from the fibroproliferative subset on HSCT experienced significant improvement in EFS compared with fibroproliferative participants on CYC (p=0.0091). In contrast, EFS did not significantly differ between CYC and HSCT arms for the participants from the normal-like subset (p=0.77) or the inflammatory subset (p=0.1). At each timepoint, we observed considerably more DEGs in HSCT arm compared with CYC arm with HSCT arm showing significant changes in immune response pathways.

CONCLUSIONS

Participants from the fibroproliferative subset showed the most significant long-term benefit from HSCT compared with CYC. This study suggests that intrinsic subset stratification of patients may be used to identify patients with SSc who receive significant benefit from HSCT.

Для цитирования: Franks Jennifer M, Martyanov Viktor, Wang Yue, Wood Tammara A, Pinckney Ashley, Crofford Leslie J, Keyes-Elstein Lynette, Furst Daniel E, Goldmuntz Ellen, Mayes Maureen D, McSweeney Peter, Nash Richard A, Sullivan Keith M, Whitfield Michael L. Machine learning predicts stem cell transplant response in severe scleroderma.. Annals of the rheumatic diseases. 2020. DOI: 10.1136/annrheumdis-2020-217033.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.